Sentences with phrase «for vaccine manufacture»
«We will be one of the first countries to get it and we have closed the gap on [lag] time for vaccine manufacture,» Sir Liam said.
http://www.politics.co.uk/ Not exact matches
The Animal Health business discovers, develops, manufactures, and markets animal health products including antibiotics, anti-inflammatory, vaccines, fertility disorder treatments, and parasiticides for cattle, swine, horses, poultry, dogs, cats, and fish.
«These findings may pave the way for the identification and manufacture of safer, single dose, high efficiency vaccines to combat current and future Ebola outbreaks,» said Thomas Geisbert, UTMB professor of Mmicrobiology and Iimmunology.
Conventional vaccines work by triggering the immune system into manufacturing antibodies against an infectious organism, but such a vaccine has proved elusive for the rapidly mutating HIV.
The findings underscore the need for targeted research to further evaluate manufacturing strategies and vaccine antigens and platforms, according to the authors.
Profectus BioSciences in Tarrytown, New York, which is developing a similar vaccine, needs some $ 2 million to produce it under good manufacturing practice standards, a prerequisite for any human study.
Still, concerns remain about whether a vaccine can actually be manufactured and approved in time for traditional flu season in the Northern Hemisphere.
Besser said officials were already taking preliminary steps toward manufacturing a vaccine against the influenza strain responsible for swine flu.
Today, except for the flu vaccine manufactured by Aventis, most vaccines contain only trace amounts of thimerosal or none.
However, Paul Keim, acting chair of the U.S. National Science Advisory Board for Biosecurity (NSABB)-- which recommended that the mutant - flu work should not be published in full — cautions that there are not enough flu vaccines or drugs worldwide, and a rapid pandemic would overwhelm our ability to manufacture more.
These vaccines usually take a long time to manufacture, and for some diseases they are too risky.
Because the individually tailored vaccine method is so different from mass - manufactured vaccines — those developed to combat infectious diseases such as smallpox — the search continues for a viable production model.
The Pilot Bioproduction Facility headed by Dr. Kenneth H. Eckels, produced small batches of vaccine candidates that were used for the preclinical studies and is currently manufacturing a vaccine lot for use in initial human clinical studies.
Two studies now suggest a new reason for the problem: The vaccine strain mutates during the manufacturing process in ways that cause mismatches with real circulating flu strains.
But for a clinical trial to start, regulators require information about how the vaccine was manufactured, and that resides with NewLink Genetics, which has been slow to release it, people familiar with the negotiations say.
Dartmouth and Aeras subsequently collaborated to develop an improved and scalable method for manufacturing the vaccine, now designated DAR - 901.
The finding will allow researchers to refine their search for new influenza strains and manufacture a yearly vaccine designed to give recipients resistance to the right ones.
This revolutionary technique is crucial for the study of the structure / function relationships of viral genes, for investigation of viral pathogenicity, and for development and manufacture of novel vaccines.
About $ 420 million of the money would go to the Office of the Assistant Secretary for Preparedness and Response within the Department of Health and Human Services for developing and manufacturing vaccines to counter pandemic flu.
«The Army was able to move so quickly in developing, manufacturing and testing a Zika vaccine because of its extensive experience with this vaccine platform and long standing investments in the understanding and mitigation of flaviviruses, like yellow fever, dating back to the founding of WRAIR,» said Dr. Kayvon Modjarrad, Zika program co-lead and associate director for Emerging Infectious Disease Threats at WRAIR's MHRP.
In WP10, iBET will be involved in activities relating to GMP - directed evaluation of vaccine candidate production processes, production scale - up for vaccine candidates, definition of specifications for pilot - scale production, product stability testing and delivery for GLP toxicology studies, as well as the evaluation of development, manufacturing and finishing documentation.
The Fraunhofer IME leads the Transnational Access 1 (TNA1) «Cross platform screening and optimization service «and the corresponding Joint Research Activity (JRA1) «Improved optimization and harmonization of cross-vector screening «both aiming at the provision of comprehensive range of different well established pro- and eukaryotic expression / production systems to identify the optimal manufacturing platform for any given vaccine candidate.
The NIAID Vaccine Research Center discovered the VRC01 antibody and manufactured it for this trial.
In WP10, iBET will be involved in the GMP - directed evaluation of vaccine candidate production processes, production scale - up for vaccine candidates, definition of specifications for pilot - scale production, product stability testing and delivery for GLP toxicology studies, as well as the evaluation of development, manufacturing and finishing documentation.
Today, however, solutions to manufacturing are unique for each vaccine.
The use of human embryonic stem cells, as opposed to patient blood, as the starting material for AST - VAC2 provides a scalable system for the production of a large number of vaccine doses in a single lot, reducing manufacturing costs, enabling «off - the - shelf» availability, and ensuring product consistency.
We also provide cell lines for use in the manufacture and testing of vaccines.
He has also participated in technology transfer projects in Brazil and India, where a vaccine formulation center has been constructed to manufacture IDRI - developed adjuvant formulations for clinical trials to evaluate malaria, leishmania, and tuberculosis vaccines.
She is also responsible for IDRI's in - house pilot manufacturing facility that produces cGMP adjuvant formulations for Phase 1 vaccine clinical trials.
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.
He currently serves as principal investigator on a $ 11.9 M contract from the National Institutes of Health (NIH) to develop a thermostable tuberculosis vaccine suitable for distribution in developing countries, involving formulation development, cGMP manufacturing, and clinical testing.
By bringing together for the first time three of Europe's leading vaccine development and manufacture companies as well as top experts from academic institutions and small and medium - sized enterprises (SMEs), the project will ultimately accelerate the development and introduction of a new generation of safer, more effective vaccines.
iBET will be involved in activities related with GMP - directed evaluation of vaccine candidate production processes, production scale - up for vaccine candidates, definition of specifications for pilot - scale production, product stability testing and delivery for GLP toxicology studies, and evaluation of development, manufacturing and finishing documentation.
Like the multidose influenza vaccines, some multidose meningococcal meningitis vaccines and tetanus toxoid (booster) vaccines (not recommended for children under six years of age) also contain thimerosal as a preservative, in amounts ranging from 12.5 to 25 micrograms per dose.27, 28 As of 2016, some other childhood vaccine preparations, such as the multidose DTaP and the DTaP / Hib combination vaccines, still utilize thimerosal in the manufacturing process.
Zoetis Inc discovers, develops, manufactures and commercializes animal health medicines and vaccines for both livestock and companion animals.
In January 2006, VaxGen granted to GSID a worldwide license to research, develop, manufacture, register, use, market, import, offer for sale, and sell its HIV vaccine candidates, including the AIDSVAX B / E vaccine.
In some cases, the vaccine can fail — if the vaccination is not stored corrected or if there was a problem in the manufacturing of the vaccine, for instance.
The first of its kind for Elanco, the new state - of - the - art facility is dedicated solely on manufacturing customized, high - quality inactivated vaccines for the poultry industry that will assist in the prevention of unique disease challenges and protection from food safety issues that can't be addressed with commercially available vaccines.
As a result of these studies, non-adjuvanted vaccines are now available; the only non-adjuvanted rabies vaccine for cats at this writing (2011) is Purevax, manufactured by Merial.
It's not surprising that more vaccines are manufactured for dogs and media hype frightens pet owners into using them.
Animal Safety Neogen's Animal Safety Division is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides and genomics testing services for the worldwide animal safety market.
Different types of equine influenza vaccine are available and manufactures have different recommendations for their vaccination program but the following is generally appropriate: -
«With the integration of Wyeth, including the Fort Dodge range of veterinary products, Pfizer's animal health business remains the world's leader in the discovery, development and manufacturing of veterinary vaccines and medicines for livestock and companion animals,» added Mr. Van Blommestein.
Provided on - site patent counsel services for their North Carolina research and manufacturing facilities, including seminal patent prosecution and worldwide portfolio management services for a multivalent polysaccharide - protein conjugate vaccine that generated sales of over $ 6 Billion in 2015.
Flublok's novel manufacturing technology allows for production of large quantities of the influenza virus protein, hemagglutinin (HA)-- the active ingredient in all inactivated influenza vaccines that is essential for entry of the virus into cells in the body.
«The new technology offers the potential for faster start - up of the vaccine manufacturing process in the event of a pandemic, because it is not dependent on an egg supply or on availability of the influenza virus.»